Researchers Attenuated Poultry Virus Using Spike Gene Swap
A new method replaces traditional egg-based vaccine production with lab-grown cell cultures.
Updated on Oct. 9, 2026 in Life Sciences
Live Poll
Should scientists prioritize developing faster methods for agricultural vaccine production?
Researchers at The Pirbright Institute have successfully attenuated a pathogenic infectious bronchitis virus by swapping its spike gene with that of the Beaudette laboratory strain. The modified virus shows promise for vaccine production by growing efficiently in Vero cell lines instead of embryonated hen's eggs.
Why it matters
Current poultry vaccine manufacturing relies on a fragile supply chain requiring over 80 passages through embryonated eggs. This research provides a pathway toward faster, more consistent vaccine development that is independent of live-egg availability.
The study utilized reverse genetics to replace the D388 virus strain's spike gene with the Beaudette spike gene. This modification allows the virus to propagate in Vero cell lines, bypassing the 80 passages currently required for production in embryonated eggs.
The players
The Pirbright Institute
A world-leading research center focused on the study and control of viral diseases in farm animals.
The details
The researchers employed reverse genetics, a molecular technique used to generate infectious viruses from cloned cDNA copies of their genomes, to swap the spike genes. By replacing the D388 gene, the team achieved a virus that produces fewer clinical signs of disease in chickens while remaining genetically stable. The modified virus triggers a controlled innate immune response, which is a fundamental requirement for effective vaccine candidates.
Timeline
October 9, 2026: The study findings were published in the Journal of Virology.
The Tech Race
This development moves the field toward cell-culture-based vaccine manufacturing, which has been a long-term goal for poultry health researchers. It directly challenges the historical reliance on embryonated eggs, which has been the industry standard for decades.
The transition to cell-culture production could eventually stabilize the cost and availability of poultry vaccines for farmers worldwide. This research-stage method must first clear regulatory and large-scale manufacturing hurdles before impacting veterinary medicine practices.
The takeaway
This study successfully demonstrates that a laboratory-modified spike protein can attenuate a pathogenic virus for safer vaccine use. The next major milestone to watch is whether this cell-culture approach can match the efficacy and production volume of existing egg-based methods.
Further reading
For more on the current state of vaccine technology, explore the Life Sciences section.
Source note: This article includes information reported by Foodagribusiness.
Live Poll
Should scientists prioritize developing faster methods for agricultural vaccine production?
